Treatment of ErbB2 breast cancer by mitochondrial targeting
Abstract Background ErbB2 breast cancer still remains an unmet need due to primary and/or acquired resistance to current treatment strategies. MEDICA compounds consist of synthetic long-chain α,ω-dicarboxylic acids previously reported to suppress breast cancer in PyMT transgenic mice. Methods MEDICA...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-07-01
|
| Series: | Cancer & Metabolism |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40170-020-00223-8 |